Trial · NCT02478359
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 34 of 34
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Body Mass Index | 12 months following randomization | Body mass index measurements were based on values closest to the 12 months post randomization |
| Other | Number of Participants With All-cause Hospitalization, Emergency Department (ED) Visits, Observation Stays and Deaths | 2 to 12 months following randomization | As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention. |
| Other | Number of Deaths Among Participants | 2 to 12 months following randomization | As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention. |
| Other | Number of Participants With All-cause Hospitalizations | 2 to 12 months following randomization | As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention. |
| Other | Number of Participants With All-cause Emergency Department Visits | 2 to 12 months following randomization | As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention. |
| Other | Number of Participants With All-cause Observation Stays | 2 to 12 months following randomization | As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention. |
| Other | Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays | 2 to 12 months randomization | As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention. |
| Other | Diastolic Blood Pressure | 6-12 months following randomization | Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization. BP obtained with temperatures of \>100F and those obtained in urgent care were excluded. |
| Other | Systolic Blood Pressure | 6-12 months following randomization | Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization. BP obtained with temperatures of \>100F and those obtained in urgent care were excluded. |
| Other | HbA1c Levels | 12 months | HbA1c levels were obtained only from diabetics and on values closest to the 12 months post randomization |
| Other | LDL Levels | 12 months | Cholesterol levels were obtained from values closest to the 12 months post randomization |
| Other | HDL Levels | 12 months | Cholesterol levels were obtained from values closest to the 12 months post randomization |
| Other | Total Cholesterol Levels | 12 months | Cholesterol levels were obtained from values closest to the 12 months post randomization |
| Other | Triglycerides Levels | 12 months | Cholesterol levels were obtained from values closest to the 12 months post randomization |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02478359/registered?page=2